News04.10.08 22:12 Age: 95 days
Ipsogen expands its U.S. market presence through licensing agreement with Quest Diagnostics Category: Leukemia, Investors
  Marseille, France, October 6th, 2008 Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.  |
|
